At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating Epirubicin Hydrochloride, External Beam Radiation Therapy, and 4 other interventions for Pleomorphic Rhabdomyosarcoma and 3 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin hydrochloride and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery may be an effective treatment for soft tissue sarcoma.
Study Details
Timeline
Interventions
Given IV
Undergo EBRT
Given IV
Correlative studies
Given PO
Undergo surgical resection